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rimary sclerosing cholangitis (PSC) is a chronic fibro-inflammatory disease of the biliary tree of unknown origin. It is a progressive disease, which causes endstage liver failure and is associated with an increased risk of cholangiocarcinoma.
Transplant-free survival is estimated between 12-21 years. 1, 2 Currently, therapy is limited to treatment of complications such as relieving biliary obstruction and orthotopic liver transplantation in case of end-stage liver disease. 3, 4 During the natural history of the disease many patients experience symptoms such as pruritus, right upper quadrant pain (RUQP), fatigue, and/or bouts of fever and jaundice due to impeded biliary drainage. In approximately 60% of cases dominant strictures (DS), which may be superimposed on diffuse ductal disease is the principal cause of these complaints. 5 . The incidence is estimated at 8-10% annually. 6 The 2015 guidelines from the American Society for Gastrointestinal Endoscopy (ASGE) on the role of endoscopic retrograde cholangiopancreatography (ERCP) state that patients with PSC and a dominant strictures should undergo ERCP with biliary sampling to assess for presence of malignancy. 7 Moreover, benign strictures respond well to endoscopic therapy. Recommendations from a recent collaboration between the European Association for Study of the Liver and the European Society of Gastrointestinal Endoscopy to develop guidelines on endoscopy in PSC are in line with the ASGE statements. 8, 9 The level of the evidence reviewed in both guidelines is however low, based only on retrospective series.
The best therapeutic approach to treat dominant strictures is not known. Both balloon dilatation and temporary stenting are employed. From the largest retrospective series on repetitive balloon dilatation one may infer that the recurrence-free rate at two years after a single session of endoscopic balloon dilatation is approximately 30%. 6 Ponsioen et al. reported that short-term stenting with a mean duration of stent placement of 11 days is safe and effective, showing improvement of cholestatic symptoms and biochemistry in 83% of patients at 8 weeks, and a re-intervention-free P M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT 5 rate of 70% at two years. 5 We hypothesized that short-term stenting is superior to balloon dilatation at preventing recurrence of DS. Therefore, the aim of the present study was to compare short-term stenting versus balloon dilatation for the treatment of dominant strictures in patients with PSC with regard to cumulative recurrence-free patency, safety, as well as short-term improvement in cholestatic symptoms and biochemistry.
Methods

Study design
We undertook a multicenter, open-label, randomized, 1:1 parallel group trial with a follow-up (FU) of 24 months. Eligible patients were randomized during ERCP when a DS was identified to either balloon dilatation or short-term stenting for a maximum of 2 weeks.
Participants
Eligible patients had a diagnosis of PSC according to the EASL 2009 criteria, 10 ascertained with MRCP, ERCP, PTC and/or liver biopsy, were between 18-75 years of age, and fulfilled at least one of the following 5 sets of criteria: (i) serum bilirubin >3xULN; (ii) progression of right upper quadrant pain (RUQP), pruritus, fatigue, and/or fever attributed to acute bacterial cholangitis by at least 1 grade according to the Amsterdam Cholestatic Complaints Score (ACCS) 5 (see supplementary table_1) within the last month together with 50 % increase of total bilirubin and/or alkaline phosphatase (ALP) within the last 4 months and absolute value > 1.2xULN; (iii) increase of 20% or more of total bilirubin and/or ALP within last 4 months and absolute value >1.2xULN together with a documented dominant appearing stricture on MRCP or ERCP < 4 months prior to screening; (iv) progression of RUQP, pruritus, fatigue, and/or fever
attributed to bacterial cholangitis by at least 1 grade within last month: together with total bilirubin and/or ALP > 1.2xULN and a documented dominant stricture on recent MRCP or ERCP < 4 months prior to screening; (v) summed cholestatic complaints score at screening of ≥3, or pruritus ≥2, or RUQP ≥2 at screening together with total bilirubin and/or ALP > 1.2xULN and a documented dominant stricture on recent MRCP or ERCP < 4 months prior to screening. Sets iv and v were added to the eligibility criteria in order to increase recruitment after additional IRB approval in March 2013 and May 2015, respectively. All eligibility sets were designed to reflect clinical practice with regard to indication for endoscopic intervention, as well as to allow for detection of relevant changes during FU. On imaging a dominant stricture was defined as any stricture arising in the extrahepatic or left/right main ducts that was deemed functionally relevant by the treating endoscopist/radiologist. In order to identify either serum bilirubin or ALP as an indicator for recurrence of the dominant stricture warranting a re-ERCP, an initial failure assessment at three months was included, (see Supplementary Appendix and supplementary figure_2). Patients who showed insufficient response with regard to improvement in cholestatic liver enzymes/cholestatic symptoms at three months would qualify as initial failure without the requirement for repeated cholangiography. 
Sample size and interim analyses
A retrospective series from Amsterdam showed a re-intervention-free rate of 70% for short-term stenting. 5 In a previous pilot study in Amsterdam, 2-year re-intervention free survival of 50% versus 17% for short-term stenting versus balloon dilatation was observed (unpublished data). Assuming that the re-intervention free survival rate at
two years would be 60% for short-term stenting versus 30% for balloon dilatation yielded a sample size of n=42 per group. Allowing for a drop-out rate of 15% rendered a total sample size of n=100 to attain a power of 80% and a 2-sided α-level of 0.05. An interim analysis by a Data Safety Monitoring Board (DSMB) was planned when 50% of the intended total number of study subjects had passed their 3-month visit. The DSMB was assigned to advise on early termination of the trial due to safety concerns, as well as on futility.
Interventions
Patients were recruited and treated at 9 academic centers across Europe.
Eligible patients underwent ERCP after written informed consent. Periprocedural antibiotic prophylaxis consisted of cefotaxime 1000 mg i.v <1 hour before the procedure, and 12 and 24 hours thereafter, or levofloxacin 500 mg orally BID within 2 hours prior to the ERCP and 12 and 24 hours thereafter.
At ERCP patients were only randomized when, in the absence of purulent bile and fever > 38.5 °C, one or more dominant stricture(s) of the common bile duct, the common hepatic duct and/or the main left or right hepatic duct were encountered and deemed amenable to both balloon-dilatation or stenting by the endoscopist. Blockrandomization in blocks of 4, to ensure even distribution among participating centers, was performed by a web-based electronic CRF. Follow-up time commenced at randomization. Prior to any intervention where possible, brush cytology was obtained of any suspicious dominant stricture. When brush cytology revealed cholangiocarcinoma or high-grade dysplasia, patient were withdrawn from the study.
Sphincterotomy was performed at the discretion of the endoscopist.
Stenting: A 10 French polyethylene stent was inserted and retrieved after 7 days (maximum time 14 days) by gastroduodenoscopy. No attempt to cannulate the biliary tree was made upon retrieval, unless the brush result was suspicious for cholanciocarcinoma or high-grade dysplasia. In case of (supra-)hilar stricturing with
imminent risk of cholangitis by closing of the contralateral system when inserting a stent an attempt should be made to insert two 7Fr stents, one to either system. If only one 7 French stent had been placed, a new ERCP was scheduled with the same perioperative antibiotic regimen and an attempt made to exchange the 7 Fr stent for a 10 French or two 7 French stents, to be retrieved after another 7 days. Balloon dilatation or Soehendra dilators to facilitate stent placement was allowed. When placement of a 10
Fr stent or at least two 7 Fr stents proved impossible after 2 ERCPs, treatment was regarded as a failure.
Balloon dilatation: DSs were dilated by placing a 4 cm 6 mm Ø biliary dilation balloon in the stricture(s). The balloon was inflated to the point that the waist disappears completely at fluoroscopy or the maximum recommended by the manufacturer for 2 minutes. Longer or serial strictures must be treated with successive dilatation down to the most distal (relative) narrowing during the same session. The use of Soehendra dilators to facilitate insertion of a balloon was allowed. If balloon dilatation with a 6 mm Ø balloon proved impossible at the first attempt, a second ERCP was scheduled after 1
week. For intrahepatic strictures a 4 mm Ø balloon was allowed. When balloon dilatation at the second attempt proved impossible, patient was regarded as an initial failure.
After the procedure patients were kept overnight for observation and iv antibiotics.
Next morning vital signs were recorded, a VAS pain scale taken, and blood drawn for hemoglobin, leucocytes, C-reactive protein, and amylase. In one center, these measurements were performed 4 hour after the procedure and, if uneventful, patients were discharged, followed by a telephone interview next morning.
Patients were reviewed at one week, and 3-monthly thereafter for 24 months.
During each visit symptoms were assessed by ACCS, SF36, adverse events were recorded, and routine bloods were drawn.
When a study subject met the decision rule for secondary failure a re-ERCP was performed: if this showed a recurrence of the original stricture then the primary endpoint was met. If no or a new DS was seen, the original treatment was still deemed successful. The new stricture could be treated at the discretion of the endoscopist, but patient's FU was censored at the time of re-ERCP. When a cholangiocarcinoma was discovered during follow-up this led to study withdrawal, as did any change in UDCA therapy. Data were censored from the date of change in UDCA therapy with regard to the primary endpoint.
Data analysis
The primary endpoint was analysed on an intention-to-treat (ITT) base by log-rank 
Results
Recruitment
From July 2011 to April 2016 80 patients were enrolled, 65 were randomized during ERCP. Recruitment is shown in Figure_1. One patient in each treatment arm was excluded from safety analysis because they did not receive treatment. Both were randomized prior to mandatory passage with a guiding catheter to show accessibility of the strictures to therapy. Also, they did not undergo a prescribed second attempt. Two 
Discussion
Since more than 20 years, there has been debate regarding the preferred modality to treat dominant strictures arising in PSC. 5, 6, 8, 13 We present the first-ever randomized trial on endoscopic therapy in PSC. We could not confirm our hypothesis that short-term stenting is superior to balloon dilatation at preventing recurrence of DS. Indeed, although the study was not designed as a non-inferiority trial the results showed that cumulative recurrence-free rates of DS over 2 years FU following single session balloon dilatation or short-term stenting were comparable with Kaplan-Meier curves and 95% confidence intervals almost completely overlapping. Even though only 65% of the predefined sample size was available for interim analysis, the DSMB calculated that the likelihood of yielding a significant contrast between the two treatment arms when 100% of the sample size would have been included would be less than 5%.
On the other hand, there was a strong safety signal in the stenting group, who experienced almost 7 times more frequently SAEs such as PEP and cholangitis/cholecystitis compared to the balloon dilatation group, while in the latter the SAE rate was 6.7%, which is consistent with earlier observations. 6, 14 This large contrast in occurrence of SAEs between groups was the main reason to terminate the trial prematurely. The overall rate of PEP as SAE in this trial was 14%, which is approximately twice the rate reported in several recent retrospective series 14, 15 , which used a similar definition of PEP, and had comparable rates of previous sphincterotomy as the major protective factor. Putative factors explaining the difference between these M A N U S C R I P T
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14 series and our trial are that the former applied stenting much less to treat DSs and had a retrospective design, which may be prone to underreporting of adverse events.
The reason for the elevated risk of PEP may be the space-occupying effect of a standard 10 Fr transpapillary stent or two 7 Fr stents obstructing the pancreatic duct in an often small and retracted papilla in PSC. This is supported by our and other's observations that PEP occurred much less frequently after previous sphincterotomy. 14, 16, 17 Likewise, 8-10mm self-expandable metallic stents for malignant obstruction in pancreatic carcinoma or distal cholangiocarcinoma are associated with an increased risk of PEP compared to 10Fr plastic stents. 18 Furthermore, a stent may block the cystic duct or the contralateral main intrahepatic duct in the often multi-strictured biliary tree of PSC patients, precipitating bacterial cholangitis. 16, 19 Our trial also yielded the first prospective data showing that both balloon dilatation and stenting of DS leads to amelioration of symptoms and significant decrease in cholestasis in the majority of patients at three months, strengthening the -thus far-low level of evidence on which the recent ASGE, EASL, and ESGE recommendations to perform therapeutic ERC in symptomatic cases are based.
An obvious advantage of balloon dilatation is that it precludes the need for further endoscopy for stent removal. However, in the largest series of balloon dilatation for DS in PSC, 1-8 (mean 1.8 ±0.2) repeated interventions were needed for successful opening of DSs. 6 A limitation of the trial is that patients underwent ERCs during follow-up only when they met the criteria of a predefined decision rule or when clinically indicated, to avoid the risks of unnecessary ERC. This generally mirrors clinical practice and justified this decision rule. Consequently, some recurrences of DSs may have been overlooked.
Balloon dilatation to facilitate stent insertion was allowed and applied in half of the patients that were randomized to stent placement. If the trial would have yielded a significant benefit of short-term stenting compared to balloon dilatation this could M A N U S C R I P T
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theoretically have constituted a confounder. However, since the trial was in fact comparing two endoscopic treatment strategies, we felt that any measure to facilitate stent placement was appropriate. Another limitation is that patients with Child-Pugh score ≥8 or Mayo Risk score >2 were excluded. It is unclear if the results can be extrapolated to such more advanced cases, because these may respond less favorably, e.g. in terms of decrease of bilirubin. More than 2/3 of patients in each group used UDCA maintenance therapy. This could potentially have blunted the biochemical response at 3 months and may have had impact on the relatively high proportion of patients that did not meet the initial response criteria.
In conclusion, endoscopic treatment of dominant strictures is efficacious in ameliorating symptoms in patients with PSC. Short-term stenting was not superior to balloon dilatation and associated with a much higher occurrence of treatment related SAEs.
Balloon dilatation should be the initial treatment of choice for dominant strictures in PSC. This may be particularly relevant in patients with an intact papilla.. Log-rank test: p=1.0 Table 2 . Changes in bilirubin, ALP, AST and cholestatic symptoms at baseline, 3 months, and changes thereof between groups.
analyses were performed in the per protocol population 'n' denotes the number for which the pertaining parameter was available.
* Mann-Whitney U test ** Fisher's exact test.
*** independent samples T-test Table 3 .
Procedure-related serious adverse events * one patient in each group was left out from the comparison because they did not receive an attempt at their allotted treatment due to failure to pass the dominant stricture with a guidewire Table 2 .
Changes in bilirubin, ALP, AST and cholestatic symptoms at baseline, 3 months, and changes thereof between groups.
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A C C E P T E D ACCEPTED MANUSCRIPT Whichever biochemical level of either ALP or bilirubin dropped more than 30% was subsequently used as indicator for recurrence during the remainder of the FU. If biochemical parameters dropped by less than 30%, the treatment was designated as initial failure. This threshold of 30% was chosen on the basis of data from 1999 in the pre-UDCA era, where we found that successful treatment of a dominant stricture with a stent was commonly associated with a drop in ALP and/or bilirubin of 30% or more. 5 However, in the trial most eligible patients used UDCA, which may be responsible for blunted dynamics in cholestatic liver enzyme levels. Planned evaluation of the first 15 patients who passed their 3 month FU learned that there were 3 patients who clearly improved with regard to their cholestatic complaints but dropped only 24-28% in ALP level, so they should be designated as initial failure, despite obvious clinical improvement. In order to bring the initial response criteria in line with the entry criteria it was decided to request an amendment from the IRB to add to the 30% biochemical improvement requirement the following: 20%-30% improvement together with improvement of at least 1 point in ACCS, (see supplementary figure 2 ). This became effective after IRB approval in May 2013 and had no bearing on the aforementioned 3 study subjects, since these were still in FU. Other reasons for initial failure were procedure related complications necessitating early reintervention, assigned treatment failure, and recurrence or persistence of the treated stricture upon early re-ERCP.
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Supplementary table 1.
Amsterdam Cholestatic Complaints Score. 5 
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Supplementary table 2.
Criteria for bacterial cholangitis according to Bilhartz 11 Major criteria
•
Body temperature > 38° Celsius 
